Peroxisome proliferator-activated receptor γ and transforming growth factor-β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22

被引:65
作者
Gupta, RA
Sarraf, P
Brockman, JA
Shappell, SB
Raftery, LA
Willson, TM
DuBois, RN
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Cellular & Dev Biol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[6] Psychiat Genom Inc, Gaithersburg, MD 20878 USA
[7] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA
[8] GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1074/jbc.M208076200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peroxisome proliferator-activated receptor gamma(PPARgamma) and transforming growth factor-beta (TGF-beta) are key regulators of epithelial cell biology. However, the molecular mechanisms by which either pathway induces growth inhibition and differentiation are incompletely understood. We have identified transforming growth factor-simulated clone-22 (TSC-22) as a target gene of both pathways in intestinal epithelial cells. TSC-22 is member of a family of leucine zipper containing transcription factors with repressor activity. Although little is known regarding its function in mammals, the Drosophila homolog of TSC-22, bunched, plays an essential role in fly development. The ability of PPARgamma to induce TSC-22 was not dependent on an intact TGF-beta1 signaling pathway and was specific for the gamma isoform. Localization studies revealed that TSC-22 mRNA is enriched in the postmitotic epithelial compartment of the normal human colon. Cells transfected with wild-type TSC-22 exhibited reduced growth rates and increased levels of p21 compared with vector-transfected cells. Furthermore, transfection with a dominant negative TSC-22 in which both repressor domains were deleted was able to reverse the p21 induction and growth inhibition caused by activation of either the PPARgamma or TGF-beta pathways. These results place TSC-22 as an important downstream component of PPARgamma and TGF-beta signaling during intestinal epithelial cell differentiation.
引用
收藏
页码:7431 / 7438
页数:8
相关论文
共 49 条
[1]   TGF-BETA EXPRESSION IN THE HUMAN COLON - DIFFERENTIAL IMMUNOSTAINING ALONG CRYPT EPITHELIUM [J].
AVERY, A ;
PARASKEVA, C ;
HALL, P ;
FLANDERS, KC ;
SPORN, M ;
MOORGHEN, M .
BRITISH JOURNAL OF CANCER, 1993, 68 (01) :137-139
[2]   Stem cells: the intestinal stem cell as a paradigm [J].
Bach, SP ;
Renehan, AG ;
Potten, CS .
CARCINOGENESIS, 2000, 21 (03) :469-476
[3]   REGULATION OF INTESTINAL EPITHELIAL-CELL GROWTH BY TRANSFORMING GROWTH-FACTOR TYPE-BETA [J].
BARNARD, JA ;
BEAUCHAMP, RD ;
COFFEY, RJ ;
MOSES, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (05) :1578-1582
[4]   Mechanisms of disease:: Role of transforming growth factor β in human disease. [J].
Blobe, GC ;
Schiemann, WP ;
Lodish, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) :1350-1358
[5]   Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells [J].
Brockman, JA ;
Gupta, RA ;
DuBois, RN .
GASTROENTEROLOGY, 1998, 115 (05) :1049-1055
[6]   Identification of a subtype selective human PPARα agonist through parallel-array synthesis [J].
Brown, PJ ;
Stuart, LW ;
Hurley, KP ;
Lewis, MC ;
Winegar, DA ;
Wilson, JG ;
Wilkinson, WO ;
Ittoop, OR ;
Willson, TM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (09) :1225-1227
[7]   DIFFERENTIAL LOCALIZATION BY INSITU HYBRIDIZATION OF DISTINCT KERATIN MESSENGER-RNA SPECIES DURING INTESTINAL EPITHELIAL-CELL DEVELOPMENT AND DIFFERENTIATION [J].
CALNEK, D ;
QUARONI, A .
DIFFERENTIATION, 1993, 53 (02) :95-104
[8]  
Chang TH, 2000, CANCER RES, V60, P1129
[9]   The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis [J].
Chung, DC .
GASTROENTEROLOGY, 2000, 119 (03) :854-865
[10]   N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.: 3.: Structure-activity relationship and optimization of the N-aryl substituent [J].
Cobb, JE ;
Blanchard, SG ;
Boswell, EG ;
Brown, KK ;
Charifson, PS ;
Cooper, JP ;
Collins, JL ;
Dezube, M ;
Henke, BR ;
Hull-Ryde, EA ;
Lake, DH ;
Lenhard, JM ;
Oliver, W ;
Oplinger, J ;
Pentti, M ;
Parks, DJ ;
Plunket, KD ;
Tong, WQ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) :5055-5069